LQT-1213
- Generic Name
- LQT-1213
Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 1, 2 or 3 Long QT Syndrome (Part 2).
Phase 1
Active, not recruiting
- Conditions
- Long QT Syndrome
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Thryv Therapeutics, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05906732
- Locations
- 🇺🇸
Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States
Phase 1 Study of LQT-1213 in Healthy Adults
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Thryv Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05759962
- Locations
- 🇺🇸
Altasciences Clinical Los Angeles, Inc., Cypress, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath